2025 Japan Asthma/Copd Combination Medication Market Revenue Opportunities Report
Description
The 2025 Japan Asthma/Copd Combination Medication Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma/COPD Combination Medication Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asthma/COPD combination medication market in Japan are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK holds about a 15.1% market share in Japan, supplying leading inhalers and biologics such as Advair and Nucala. AstraZeneca follows closely with key products like Symbicort and Fasenra, also investing in digital inhaler partnerships to enhance treatment adherence. Boehringer Ingelheim is known for its COPD-focused drugs, including Spiriva and Stiolto, with robust research and development programs emphasizing COPD management. Novartis, though smaller, contributes with inhalers like QVAR RediHaler and pipelines of COPD biologics, maintaining a strong presence in Japan’s respiratory therapeutics market.
These companies’ dominance is driven by the rising prevalence of chronic respiratory diseases in Japan's aging population, supported by government initiatives and technological advances in drug delivery and digital health. Combination medications that merge bronchodilators and corticosteroids are increasingly preferred due to their improved efficacy and convenience, further boosting market growth. The Japan Asthma and COPD market was valued at around USD 2 billion in 2024, with steady expansion expected through 2035 as demand grows for effective, patient-friendly treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma/COPD Combination Medication Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asthma/COPD combination medication market in Japan are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK holds about a 15.1% market share in Japan, supplying leading inhalers and biologics such as Advair and Nucala. AstraZeneca follows closely with key products like Symbicort and Fasenra, also investing in digital inhaler partnerships to enhance treatment adherence. Boehringer Ingelheim is known for its COPD-focused drugs, including Spiriva and Stiolto, with robust research and development programs emphasizing COPD management. Novartis, though smaller, contributes with inhalers like QVAR RediHaler and pipelines of COPD biologics, maintaining a strong presence in Japan’s respiratory therapeutics market.
These companies’ dominance is driven by the rising prevalence of chronic respiratory diseases in Japan's aging population, supported by government initiatives and technological advances in drug delivery and digital health. Combination medications that merge bronchodilators and corticosteroids are increasingly preferred due to their improved efficacy and convenience, further boosting market growth. The Japan Asthma and COPD market was valued at around USD 2 billion in 2024, with steady expansion expected through 2035 as demand grows for effective, patient-friendly treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
